Vertex has recorded some 25,000 prescriptions for Journavx since its January approval and is in the process of getting big ...

Vertex Pharmaceuticals Incorporated’s VRTX first-quarter results were weak as it missed estimates for both earnings and sales ...

The new campaign stars former NFL quarterback Alex Smith, whose leg injury during a 2018 game led to a case of ...

Vertex also picked up a positive Committee for Medicinal Products for Human Use (CHMP) opinion for Alyftrek. As a result, it's looking for European Commission approval for the drug in the second half ...

Vertex Pharmaceuticals stock was falling sharply Tuesday after the biotech company reported first-quarter earnings that ...

Vertex Pharmaceuticals sees brighter prospects despite Q1 misses, with promising launches, pipeline progress, and upgraded ...

New non-opioid pain killer get FDA approval for acute pain. Patients are taking note. Also demonstrated efficacy, just not ...

Vertex's diversification efforts are most visible in the progress of its pain management portfolio. Read why I rate VRTX ...

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reports Q1 earnings with $4.32 EPS and $2.85B revenue. Stock up 25.48% in past year, ...

Shares of Vertex Pharmaceuticals (VRTX -11.98%) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. The sharp decline came after the company announced its 2025 first-quarter result ...

For Vertex Pharmaceuticals, the first quarter of 2025 brought good news and bad news. | Despite positive early signs for its ...

Vertex Pharmaceuticals Inc (VRTX) reports a 3% revenue increase, driven by US growth and new product launches, despite ...